XML 63 R47.htm IDEA: XBRL DOCUMENT
v3.26.1

Other Intangible Assets (Details) - USD ($) |  |  |  | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Apr. 29, 2024 | Apr. 26, 2024 | Aug. 15, 2023 | Dec. 31, 2024 | Jun. 06, 2025
Other Intangible Assets |  |  |  |  |  |
Accrual for intangible asset milestone obligation |  |  |  |  | $ 2,000,000 |
Issuance of common stock as consideration for licensing agreement | [1] |  |  |  | 436,809 |
Change in fair value of equity consideration payable |  |  |  |  | (1,240,800) |
Impairment of intangible assets |  |  |  |  | 6,100,000 |
License | Formosa Pharmaceuticals Inc |  |  |  |  |  |
Other Intangible Assets |  |  |  |  |  |
Percentage of product approved by FDA |  |  |  | 0.05% |  |
Upfront payment |  |  |  | $ 2,000,000 |  |
Accrual for intangible asset milestone obligation |  |  | $ 2,000,000 |  | 2,000,000 |
Upfront payment paid in cash |  |  | $ 1,000,000 | $ 1,000,000 |  |
Issuance of common stock as consideration for licensing agreement (in shares) |  | 7,668 |  | 6,097 |  |
Legal expenses capitalized |  |  |  | $ 122,945 |  |
Maximum amount payable upon achievement of certain development milestones |  |  |  | 4,000,000 |  |
Maximum amount payable upon achievement of certain sales milestones |  |  |  | 80,000,000 |  |
Initial development milestone payment which trigger FDA approval |  |  |  | $ 2,000,000 | 2,000,000 |
Issuance of common stock as consideration for licensing agreement |  | $ 400,000 |  |  |  |
Change in fair value of equity consideration payable |  |  |  |  | 600,000 |
Impairment of intangible assets |  |  |  |  | $ 6,100,000 |
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] |  |  |  |  | Other Asset Impairment Loss |
Total obligations |  |  |  |  |  | $ 2,200,000
[1] | Shares issued as partial consideration for License Agreement with Formosa Pharmaceuticals Inc.

X
- Definition Amount of accrual related to intangible asset recorded in milestone obligation as part of non-cash investing and financing activity. + References No definition available. + Details
Name: | hypd_AccrualForIntangibleAssetsMilestoneObligation
Namespace Prefix: | hypd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of change in fair value of equity consideration payable. + References No definition available. + Details
Name: | hypd_ChangeInFairValueOfEquityConsiderationPayable
Namespace Prefix: | hypd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of initial development milestone payment which trigger FDA approval. + References No definition available. + Details
Name: | hypd_InitialDevelopmentMilestonePaymentTriggerForFdaApproval
Namespace Prefix: | hypd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of license obligations payable for intangible assets. + References No definition available. + Details
Name: | hypd_IntangibleAssetsLicenseObligationsPayable
Namespace Prefix: | hypd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Legal expenses capitalized. + References No definition available. + Details
Name: | hypd_LegalExpensesCapitalized
Namespace Prefix: | hypd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum amount payable upon achievement of certain development milestones. + References No definition available. + Details
Name: | hypd_MaximumAmountPayableUponAchievementOfCertainDevelopmentMilestones
Namespace Prefix: | hypd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum amount payable upon achievement of certain sales milestones. + References No definition available. + Details
Name: | hypd_MaximumAmountPayableUponAchievementOfCertainSalesMilestones
Namespace Prefix: | hypd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of product approved by FDA. + References No definition available. + Details
Name: | hypd_PercentageOfProductApprovedByFda
Namespace Prefix: | hypd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represent stock issued period shares licensing agreements. + References No definition available. + Details
Name: | hypd_StockIssuedDuringPeriodSharesLicensingAgreements
Namespace Prefix: | hypd_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represent stock issued during period value licensing agreements. + References No definition available. + Details
Name: | hypd_StockIssuedDuringPeriodValueLicensingAgreements
Namespace Prefix: | hypd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of upfront payment made. + References No definition available. + Details
Name: | hypd_UpfrontPayment
Namespace Prefix: | hypd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment paid in cash + References No definition available. + Details
Name: | hypd_UpfrontPaymentPaidInCash
Namespace Prefix: | hypd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
Namespace Prefix: | us-gaap_
Data Type: | enum2:enumerationSetItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 38 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 31 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 55 -Paragraph 40 -SubTopic 30 -Topic 350 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=hypd_FormosaPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |